Literature DB >> 8025775

Persistent adenoviral infection and chronic airway obstruction in children.

V Macek1, J Sorli, S Kopriva, J Marin.   

Abstract

Previous studies from several laboratories have established that adenovirus is a common cause of severe childhood bronchiolitis. The observation that children with an established history of bronchiolitis subsequently developed unremitting airways obstruction even after adequate steroid therapy led us to postulate that this bronchial obstruction might be due to persistence of an adenoviral infection. This hypothesis was tested by performing bronchoalveolar lavage (BAL) on a group of 34 children with a mean age of 5 yr (range, 14 mo to 14 yr) who showed an unfavorable response to standard corticosteroid and bronchodilator therapy. Analysis of cytospin preparations of BAL fluid at the light-microscopic level, using a monoclonal antibody to detect adenoviral antigens, demonstrated that capsid protein was present in 31 of 34 (94%) of the children examined. Limited repeat studies within 1 yr showed 6 of 8 (75%) were positive twice when tested on two occasions, and that three were positive in all occasions when sampled three times. Cultures of the BAL fluid were also positive for adenovirus in six of six cultures performed, indicating that the virus was in some cases replicating. Similar studies of control patients without persistent asthma showed no evidence of adenovirus. We conclude that persistent and/or latent adenoviral infection may contribute to the pathogenesis of childhood asthma in which there is an unfavorable response to steroid and bronchodilatation therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8025775     DOI: 10.1164/ajrccm.150.1.8025775

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  35 in total

1.  Bak and Bax function to limit adenovirus replication through apoptosis induction.

Authors:  Andrea Cuconati; Kurt Degenhardt; Ramya Sundararajan; Alan Anschel; Eileen White
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Investigation of the child with interstitial lung disease.

Authors:  D Spencer; A Fall
Journal:  Indian J Pediatr       Date:  2000-02       Impact factor: 1.967

3.  Pulmonary immunity to viral infection: adenovirus infection of lung dendritic cells renders T cells nonresponsive to interleukin-2.

Authors:  Allison T Thiele; Tina L Sumpter; Joanna A Walker; Qi Xu; Cheong-Hee Chang; Robert L Bacallao; Rajesh Kher; David S Wilkes
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Effects of allergic airway disease on mouse adenovirus type 1 respiratory infection.

Authors:  Victoria E Anderson; Yn Nguyen; Jason B Weinberg
Journal:  Virology       Date:  2009-06-28       Impact factor: 3.616

5.  Diagnosing and treating chesty infants. A short trial of inhaled corticosteroid is probably the best approach.

Authors:  D Cochran
Journal:  BMJ       Date:  1998-05-23

Review 6.  Mechanisms of virus induced exacerbations of asthma.

Authors:  J M Corne; S T Holgate
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

Review 7.  Infection in severe asthma exacerbations and critical asthma syndrome.

Authors:  Christian E Sandrock; Andrew Norris
Journal:  Clin Rev Allergy Immunol       Date:  2015-02       Impact factor: 8.667

8.  Increased tumor necrosis factor-alpha (TNF-alpha) gene expression in parainfluenza type 1 (Sendai) virus-induced bronchiolar fibrosis.

Authors:  E W Uhl; L L Moldawer; W W Busse; T J Jack; W L Castleman
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

9.  Molecular evolution of human species D adenoviruses.

Authors:  Christopher M Robinson; Donald Seto; Morris S Jones; David W Dyer; James Chodosh
Journal:  Infect Genet Evol       Date:  2011-05-05       Impact factor: 3.342

10.  Viral induction of a chronic asthma phenotype and genetic segregation from the acute response.

Authors:  Michael J Walter; Jeffrey D Morton; Naohiro Kajiwara; Eugene Agapov; Michael J Holtzman
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.